PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
A new report from PhRMA outlines potential growth trajectories affecting the biopharmaceutical industry.
The Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the US biopharmaceutical sector. Developed by the Battelle Technology Partnership Practice, the report finds that coverage and payment policies, a science-based regulatory system, and strong intellectual property (IP) protections drive US leadership in biopharmaceutical innovation, and if negative trends in these key policy areas continue, jobs supported by the industry would decrease over the next decade. However, if reasonable pro-innovation policies are pursued, the biopharmaceutical sector stands to retain and addover 300,000 jobs by 2021. The report combines quantitative data with inputfrom industry leaders.
As the ability to innovate is increasingly becoming the most important determinant of a nation’s future potential for economic growth and global competitiveness, the biopharmaceutical industry stands out among manufacturing industries as an example for future economic growth, the report says. Currently, the biopharmaceutical industry supports a total of 3.4 million jobs across the US economy, including over 810,000 direct jobs, contributes $789billion in economic output, and is responsible for about one in five dollars spent on R&D by US businesses. To put into greater context, biopharmaceutical companies invested more than nine times the amount of R&D per employee than manufacturing industries overall from 2000 to 2010.
Not only have PhRMA member companies invested an estimated $51.1 billion in R&D in 2013, representing the majority of all biopharmaceutical R&D spending in the US, but the medicines developed by the industry play an important role in helping control other health care costs. For example, theCongressional Budget Office recently adopted a scoring change that credits Medicare policies that increase use of medicines with savings on other Medicare costs. Similarly, Harvard researchers report savings on hospital and nursing facility costs of about $1200 per newly insured Part D beneficiary in 2007.This equals overall Medicare savings of $13.4 billion, more than one quarter of Part D’s total cost during the program’s first full year.
Source: Pharmaceutical Research and Manufacturers of America
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
